CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$41,902 | -$33,882 | -$808 | -$28,778 |
| Dep. & Amort. | $56 | $215 | $211 | $199 |
| Deferred Tax | -$3,684 | -$2,094 | -$1,990 | $0 |
| Stock-Based Comp. | $4,669 | $3,724 | $3,350 | $3,487 |
| Change in WC | $6,963 | $1,049 | -$30,818 | $28,438 |
| Other Non-Cash | $6,518 | $4,843 | $4,618 | $3,085 |
| Operating Cash Flow | -$27,380 | -$26,145 | -$25,437 | $6,431 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$180 | $0 | -$70 | -$195 |
| Net Acquisitions | $0 | $0 | -$789 | -$1,318 |
| Inv. Purchases | -$115,928 | -$29,538 | -$39,111 | -$121,097 |
| Inv. Sales/Matur. | $74,001 | $44,999 | $39,900 | $60,650 |
| Other Inv. Act. | $0 | $15,461 | $789 | $1,318 |
| Investing Cash Flow | -$42,107 | $15,461 | $719 | -$60,642 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $2,729 | $243,224 | $1,050 | $92,360 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $2,729 | $248,923 | $1,050 | $93,070 |
| Financing Cash Flow | $2,729 | $248,923 | $1,050 | $93,070 |
| Forex Effect | -$428 | $0 | $27,018 | $0 |
| Net Chg. in Cash | -$67,186 | $238,239 | -$23,668 | $38,859 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $273,721 | $35,482 | $59,150 | $20,291 |
| End Cash | $206,535 | $273,721 | $35,482 | $59,150 |
| Free Cash Flow | -$27,560 | -$26,145 | -$25,507 | $6,236 |